GENUS ONCOLOGY - THE MUC1-C COMPANY
  • Company
    • Mission
    • About Us
    • Genus Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Clinical and Research Partners
    • Contact
    • Sitemap
  • Why Target MUC1-C?
  • Clinical Trials
    • Summary
    • GO-203
    • Phase 2 AML Clinical Trial
  • The Science
    • Overview
    • MUC1 in Human Cancer: The Numbers
    • MUC1 in Human Cancer: Overexpression
    • Target for Carcinoma Stem-Like Cell
    • Target for Leukemia Stem Cell
    • MUC1-C is an Attractive Target for Reversing Immune Evasion
    • Intellectual Property
  • Programs
    • Pipeline
    • Targeting the Cytoplasmic Domain
    • Targeting the Extracellular Domain
    • Biomarker Program
  • News & Publications
    • News
    • Publications >
      • Complete Listing
      • Role of MUC1-C in Signal Transduction
      • Role of MUC1-C in Epigenetic Regulation
      • Role of MUC1-C in Immune Evasion
      • MUC1 Vaccine
      • MUC1-C in Stem-like Cells
      • MUC1-C inhibitor formulated in Nanoparticles
      • MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
      • MUC1-C is a druggable target

The MUC1-C COMPANY

Novel IMMUNOtherapeutics that target the MUC1-C ONCOPROTEIN

​WHY TARGET MUC1-C?

WHY TARGET MUC1-C ?
Picture
Genus Oncology is a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class agents against the MUC1-C oncoprotein for the treatment of patients with refractory cancers.

We have assembled an experienced team that is committed to developing novel therapeutics targeting MUC1-C using different approaches to address a significant unmet medical need.   More...

Picture

Clinical Trials

We are currently recruiting patients for a Phase 2 study for patients with AML (acute myeloid leukemia).
​
Picture

The Science

The MUC1-C heterodimeric protein is aberrantly overexpressed at high levels in most human carcinomas and certain hematologic malignancies.​
Picture

News and Publications

Current news items and a complete list of scientific publications supporting the work at Genus Oncology, LLC.
​

Company

About Us
Management
Board of Directors
​Contact
​
Sitemap

Science

MUC1-C
Why Target?
MUC1-C in Stem Cells
Publications

Programs

Targeting
Biomarker
Intellectual Property

Pipeline

Pipeline
​Clinical Trials

News

News
​Publications
© COPYRIGHT 2020 ALL RIGHTS RESERVED.
  • Company
    • Mission
    • About Us
    • Genus Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Clinical and Research Partners
    • Contact
    • Sitemap
  • Why Target MUC1-C?
  • Clinical Trials
    • Summary
    • GO-203
    • Phase 2 AML Clinical Trial
  • The Science
    • Overview
    • MUC1 in Human Cancer: The Numbers
    • MUC1 in Human Cancer: Overexpression
    • Target for Carcinoma Stem-Like Cell
    • Target for Leukemia Stem Cell
    • MUC1-C is an Attractive Target for Reversing Immune Evasion
    • Intellectual Property
  • Programs
    • Pipeline
    • Targeting the Cytoplasmic Domain
    • Targeting the Extracellular Domain
    • Biomarker Program
  • News & Publications
    • News
    • Publications >
      • Complete Listing
      • Role of MUC1-C in Signal Transduction
      • Role of MUC1-C in Epigenetic Regulation
      • Role of MUC1-C in Immune Evasion
      • MUC1 Vaccine
      • MUC1-C in Stem-like Cells
      • MUC1-C inhibitor formulated in Nanoparticles
      • MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
      • MUC1-C is a druggable target